Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

NCT00115739 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Study was closed early due to slow accrual

Conditions

Thyroid Cancer

Interventions

DRUG: Imatinib

Sponsor

University of Michigan Rogel Cancer Center